Tokyo, Japan, January 28, 2008 (U.S. Time) - Eisai Co., Ltd. (Tokyo, TSE 4523) (“Eisai”), a research-based human health care (hhc) company, today announced the successful …

MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceutical products for oncology and acute care …

MGI Pharma, Inc. is an oncology-focused biopharmaceutical company that acquires, develops, and markets specialty pharmaceutical and medical products for therapeutic markets of unmet …

MGI Pharma is an oncology-focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients. Use the …

Information on acquisition, funding, investors, and executives for MGI Pharma. Use the PitchBook Platform to explore the full profile.

Find company research, competitor information, contact details & financial data for MGI PHARMA of Baltimore, MD. Get the latest business insights from Dun & Bradstreet.

MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops, and commercializes proprietary products that address the …

MGI Pharma Inc. is a biopharmaceutical subsidiary of Eisai of North America founded in 14 November 1979 [1] as a company of itself, before the successful 3.9B USD acquisition by …

MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops, and commercializes proprietary products that address the …

MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceutical products for oncology and acute care …